MET and gastric cancer: In a phase 2 single‐arm trial, second‐line AMG‐337 (a small‐molecule MET inhibitor) resulted in an overall response rate (ORR) of 18% in patients with pretreated MET‐amplified GC, with a median PFS of 3.4 months.21